nach oben

Erschienen in:

29.03.2021 | TAVI | Zertifizierte Fortbildung

Strukturelle Herzfehler

Antithrombotische Therapie nach perkutaner Behandlung

verfasst von: Dr. med. Erion Xhepa, Costanza Pellegrini, Dr. med. Tobias Rheude, Salvatore Cassese

Erschienen in: CardioVasc | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Auszug

Die kathetergestützte Behandlung von strukturellen Herzfehlern hat sich als weitverbreitete Alternative zur chirurgischen Therapie entwickelt. Die optimale Gerinnungshemmung nach diesen Eingriffen ist jedoch bis dato unklar, da ein erhöhtes Risiko thromboembolischer Ereignisse einem erhöhten Blutungsrisiko gegenübersteht. Die Suche nach der individuell optimalen antithrombotischen Therapie hat somit große praktische Relevanz. …

Schömig A, Neumann FJ, Kastrati A et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med. 1996;334:1084-9

Leon MB, Baim DS, Popma JJ et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med. 1998;339:1665-71

Mack MJ, Leon MB, Thourani VH et al. Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. N Engl J Med. 2019;380:1695-705

Smith CR, Leon MB, Mack MJ et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med. 2011;364:2187-98

Leon MB, Smith CR, Mack MJ et al. Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med. 2016;374:1609-20

Van Mieghem NM, El Faquir N, Rahhab Z et al. Incidence and predictors of debris embolizing to the brain during transcatheter aortic valve implantation. JACC Cardiovasc Interv. 2015;8:718-24

Généreux P, Cohen DJ, Mack M et al. Incidence, predictors, and prognostic impact of late bleeding complications after transcatheter aortic valve replacement. J Am Coll Cardiol. 2014;64:2605-15

Baumgartner H, Falk V, Bax JJ et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017;38:2739-91

Nishimura Rick A., Otto Catherine M., Bonow Robert O. et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary. Circulation. 2014;129:2440-92

10.

Hochholzer W, Nührenberg T, Flierl U et al. Antithrombotische Therapie nach strukturellen kardialen Interventionen. Kardiologe. 2020; https://doi.org/10.1007/s12181-020-00441-w

11.

Ussia GP, Scarabelli M, Mulè M et al. Dual antiplatelet therapy versus aspirin alone in patients undergoing transcatheter aortic valve implantation. Am J Cardiol. 2011;108:1772-6

12.

Stabile E, Pucciarelli A, Cota L et al. SAT-TAVI (single antiplatelet therapy for TAVI) study: a pilot randomized study comparing double to single antiplatelet therapy for transcatheter aortic valve implantation. Int J Cardiol. 2014;174:624-7

13.

Rodés-Cabau J, Masson J-B, Welsh RC et al. Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomized Clinical Trial. JACC Cardiovasc Interv. 2017;10:1357-65

14.

Brouwer J, Nijenhuis VJ, Delewi R et al. Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation. N Engl J Med. 2020;383:1447-57

15.

Pellegrini C, Xhepa E, Ndrepepa G et al. Antithrombotic therapy with or without clopidogrel after transcatheter aortic valve replacement. A meta-analysis of randomized controlled trials. Clin Res Cardiol. 2020. Available at: http://dx.doi.org/10.1007/s00392-020-01791-x.

16.

Amat-Santos IJ, Rodés-Cabau J, Urena M et al. Incidence, predictive factors, and prognostic value of new-onset atrial fibrillation following transcatheter aortic valve implantation. J Am Coll Cardiol. 2012;59:178-88

17.

Auffret V, Regueiro A, Del Trigo M et al. Predictors of Early Cerebrovascular Events in Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement. J Am Coll Cardiol. 2016;68:673-84

18.

Nijenhuis VJ, Brouwer J, Delewi R et al. Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation. N Engl J Med. 2020;382:1696-707

19.

Rheude T, Pellegrini C, Stortecky S et al. Meta-Analysis of Bioprosthetic Valve Thrombosis After Transcatheter Aortic Valve Implantation. Am J Cardiol. 2021;138:92-9

20.

Chakravarty T, Søndergaard L, Friedman J et al. Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study. Lancet. 2017;389:2383-92

21.

Dangas GD, Tijssen JGP, Wöhrle J et al. A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement. N Engl J Med. 2020;382:120-9

22.

Feldman T, Foster E, Glower DD et al. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med. 2011;364:1395-406

23.

Attizzani GF, Ohno Y, Capodanno D et al. Extended use of percutaneous edge-to-edge mitral valve repair beyond EVEREST (Endovascular Valve Edge-to-Edge Repair) criteria: 30-day and 12-month clinical and echocardiografic outcomes from the GRASP (Getting Reduction of Mitral Insufficiency by Percutaneous Clip Implantation) registry. JACC Cardiovasc Interv. 2015;8:74-82

24.

Stone GW, Lindenfeld J, Abraham WT et al. Transcatheter Mitral-Valve Repair in Patients with Heart Failure. N Engl J Med. 2018;379:2307-18

25.

Pagnesi M, Moroni F, Beneduce A et al. Thrombotic Risk and Antithrombotic Strategies After Transcatheter Mitral Valve Replacement. JACC Cardiovasc Interv. 2019;12:2388-401

26.

Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg. 1996;61:755-9

27.

Glikson M, Wolff R, Hindricks G et al. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion - an update. EuroIntervention. 2020;15:1133-80

28.

Patti G, Sticchi A, Verolino G et al. Safety and Efficacy of Single Versus Dual Antiplatelet Therapy After Left Atrial Appendage Occlusion. Am J Cardiol. 2020;134:83-90

29.

Windecker S, Wahl A, Chatterjee T et al. Percutaneous closure of patent foramen ovale in patients with paradoxical embolism: long-term risk of recurrent thromboembolic events. Circulation. 2000;101:893-8

30.

Baumgartner H, De Backer J, Babu-Narayan SV et al. 2020 ESC Guidelines for the management of adult congenital heart disease. Eur Heart J. 2020; https://doi.org/10.1093/eurheartj/ehaa554.

31.

Alushi B, Lauten A, Cassese S et al. Patent foramen ovale closure versus medical therapy for prevention of recurrent cryptogenic embolism: updated meta-analysis of randomized clinical trials. Clin Res Cardiol. 2018;107:788-98

32.

Søndergaard L, Kasner SE, Rhodes JF et al. Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke. N Engl J Med. 2017;377:1033-42

33.

Carroll JD, Saver JL, Thaler DE et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med. 2013;368:1092-100

34.

Mas J-L, Derumeaux G, Guillon B et al. Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke. N Engl J Med. 2017;377:1011-21

35.

Pristipino C, Sievert H, D'Ascenzo F et al. European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism. EuroIntervention. 2019;14:1389-402

Titel: Strukturelle Herzfehler
Antithrombotische Therapie nach perkutaner Behandlung
verfasst von: Dr. med. Erion Xhepa
Costanza Pellegrini
Dr. med. Tobias Rheude
Salvatore Cassese
Publikationsdatum: 29.03.2021
Verlag: Springer Medizin
Schlagwörter: TAVI
Clopidogrel
Erschienen in: CardioVasc / Ausgabe 2/2021
Print ISSN: 1617-4933
Elektronische ISSN: 1618-3851
DOI: https://doi.org/10.1007/s15027-021-3470-z

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2021

COVID-19: Studie mit Colchicin wegen fehlender Wirkung gestoppt

Vorsicht bei Antidepressiva nach intrazerebralen Blutungen

Die Rechtsherzinsuffizienz ist eine Systemerkrankung

Eine Monsterpille zur Prophylaxe bei Herzgesunden

Myokarditiden bei SARS-CoV-2-positiven Leistungssportlern offenbar selten

Neuer Myosin-Aktivator hat bei Herzinsuffizienz moderate Effekte